By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week Paris, 8 December 2016- ABIVAX, an innovative biotechnology company targeting the immune system to eliminate viral disease, announced that the Company presented new preclinical data on ABX464, ABIVAX's first-in-class drug candidate for a functional cure of patients with HIV/A
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week Castle Creek Pharmaceuticals, LLC, a global company dedicated to delivering transformative therapies to patients with dermatologic and head/neck orphan diseases and underserved conditions, announced completion of an exclusive license agreement for all U.S. rights to Arlevert
LOS ANGELES Wednesday AHF lauded the publication of clinical trial results in the journal Lancet which showed 100 percent efficacy in preventing Ebola virus infection among study participants who received an experimental vaccine in Sierra Leone and Guinea. Every year the world collectively spends almost $2 trillion on defense and only $36 billio
Humacyte, an innovator in biotechnology and regenerative medicine, announced today the initiation of a U.S. Phase II arterial bypass clinical trial of HUMACYL, its investigational human acellular vessel, to test the safety and efficacy as a lower extremity arterial bypass vessel in patients with peripheral arterial disease. The initiation of the Ph
Pharmaceutical company Lupin has received tentative approval from the United States Food and Drug Administration to market its cholesterol lowering Pitavastatin tablets in the American market. has received approval for Pitavastatin tablets in the strength of 1 milligram, 2 mg and 4 mg. Pitavastatin is a generic version of Kowa's Livalo tablets in t
This file photo taken on March 10, 2015, shows a woman getting vaccinated at a health center in Conakry, Guinea, during the first clinical trials of the VSV-EBOV vaccine against the Ebola virus. China says its first domestically-developed Ebola vaccine is a major medical breakthrough as it passed the Phase-II clinical test and gains permission for
In 2016, many new and useful medications got FDA approval. My articles are syndicated worldwide, but I'm only listing English drug names so please ask your local pharmacist to translate the medication name for your country. So the FDA approved this injectable drug to help people who have been exposed from infected animals, contaimated animal produc
Araim Pharmaceuticals has formed a long-term strategic partnership with Vault Bioventures to facilitate the advancement to market of its novel peptide library which targets devastating injuries and chronic diseases underserved by current therapies. This new strategic collaboration is expected to leverage the expertise of Araim Pharmaceuticals in.
Release date- 28122015- Basilea Pharmaceutica Ltd. today provided an update on the planned clinical phase 3 development program for its antibiotic ceftobiprole in the United States and reported completion of patient recruitment and interim data from the ongoing phase 1/ 2 a study with the intravenous formulation of its oncology drug candidate BAL10
-Princeton, New Jersey and Lund, Sweden 30 December 2015 Braeburn. Pharmaceuticals and Camurus announce that the first patient has been randomized. in the double blind Phase 3 efficacy trial of CAM2038 in opioid-dependent.
By a News Reporter-Staff News Editor at Politics& Government Week Clovis Oncology, Inc. announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act date for Clovis' New Drug Application for rociletinib by the standard extension period of three months with the new goal date of June 28, 2016. Clovis Oncology
Dec. 31 Israeli placenta-based cell therapy developer Pluristem Therapeutics Ltd. has been awarded orphan drug status by the US Food and Drug Administration for its PLX-PAD cells treatment for severe preeclampsia. We are encouraged by the US FDA designation that demonstrates Pluristem's commitment to the program and the potential promise it holds
Global Blood Therapeutics, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, announced today that the U.S. Food and Drug Administration has granted orphan drug designation for GBT440 for the treatment of patients with sickle cell disease.
By a News Reporter-Staff News Editor at Politics& Government Week Since 2006, the number of industry-sponsored clinical trials studying the benefits and harms of medical treatments has risen dramatically, while the number of clinical trials funded by the National Institutes of Health has fallen substantially, according to new Johns Hopkins Bloomb
NEW YORK, NY/ ACCESSWIRE/ December 31, 2015/ LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of TetraLogic Pharmaceuticals, a clinical-stage biopharmaceutical company developing therapies for cancer and infectious diseases.
The Report Deep Brain Stimulators- Medical Devices Pipeline Assessment, 2015 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants.Albany, NY 12/31/2015 MarketResearchReports.Biz presents this most up-to-date research on "Deep Brain Stimulators- Medical Devices Pipeline Assessme
The Report Proliferative Vitreoretinopathy Global Clinical Trials Review, H2, 2015 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants.Albany, NY 12/31/2015 MarketResearchReports.Biz presents this most up-to-date research on "Proliferative Vitreoretinopathy Global Clinical...
-NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system disorders, today announced the start of patient enrollment in a first efficacy trial of ND0612H, the companys continuously administered subcutaneous levodopa/carbidopa solution. This treatment is intended to be an alternative to current treatments..
-PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today a shareholder update on PharmaCytes pancreatic cancer and diabetes programs. Manuel Hidalgo, and experts at Translational Drug...
Researchers Submit Patent Application, "Method of Treating an Ocular Disease and Compositions Effective for Treating an Ocular Disease", for Approval. By a News Reporter-Staff News Editor at Women's Health Weekly From Washington, D.C., NewsRx journalists report that a patent application by the inventors Karla, Pradeep K.; Mangat, Harpal S., filed
Tenders are invited for Rfa Fibre For Bipolar Intraluminal Application For Varicose Veins Detail Specification: Us Fda/ European Ce Approved Quality. Instructions/Remarks: All The Firms Participating In E-Tender Enquiry To Upload The Details Of The Offered Item In The Form Of Scanned Copy Of The Photo Of The Offered Item Showing All Relevant Detail
By a News Reporter-Staff News Editor at Women's Health Weekly Roche announced that it has filed a direct de novo application to the U.S. Food and Drug Administration for a fully automated Anti-Mullerian assay for use on Roche's full portfolio of laboratory analyzers. Alan Wright, Chief Medical Officer, Roche Diagnostics Corporation. The assay is
Teligent, Inc., a New Jersey- based specialty generic pharmaceutical company, today announced it has submitted its fourteenth and fifteenth abbreviated new drug applications to the U.S. Food and Drug Administration of 2015, which brings the Company's total number of ANDA submissions now pending at the FDA to thirty-three. We believe our current p
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced that the U.S. Food and Drug Administration has granted the Company s PLX-PAD cells Orphan Drug Designation in the treatment of severe preeclampsia. Attainment of Orphan Drug Designation for our cells in severe preeclampsia exemplifies o